Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 1
2003 2
2004 2
2005 4
2006 8
2007 8
2008 7
2009 8
2010 4
2011 7
2012 7
2013 7
2014 7
2015 4
2016 4
2017 9
2018 6
2019 6
2020 3
2021 5
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

100 results
Results by year
Filters applied: . Clear all
Page 1
Potential therapeutic uses of rexinoids.
Leal AS, Reich LA, Moerland JA, Zhang D, Liby KT. Leal AS, et al. Among authors: liby kt. Adv Pharmacol. 2021;91:141-183. doi: 10.1016/bs.apha.2021.01.004. Epub 2021 Mar 4. Adv Pharmacol. 2021. PMID: 34099107 Review.
NRF2 as an Emerging Therapeutic Target.
Copple IM, Dinkova-Kostova AT, Kensler TW, Liby KT, Wigley WC. Copple IM, et al. Among authors: liby kt. Oxid Med Cell Longev. 2017;2017:8165458. doi: 10.1155/2017/8165458. Epub 2017 Jan 31. Oxid Med Cell Longev. 2017. PMID: 28250892 Free PMC article. No abstract available.
PARP inhibitors for chemoprevention--reply.
To C, Sporn MB, Liby KT. To C, et al. Among authors: liby kt. Cancer Prev Res (Phila). 2014 Nov;7(11):1172. doi: 10.1158/1940-6207.CAPR-14-0264. Cancer Prev Res (Phila). 2014. PMID: 25368012 Free article. No abstract available.
Prolactin as an autocrine/paracrine growth factor in human cancer.
Ben-Jonathan N, Liby K, McFarland M, Zinger M. Ben-Jonathan N, et al. Among authors: liby k. Trends Endocrinol Metab. 2002 Aug;13(6):245-50. doi: 10.1016/s1043-2760(02)00603-3. Trends Endocrinol Metab. 2002. PMID: 12128285 Review.
100 results